Pangenotypic DAA Therapy Safe, Effective in Children with HCV, Study Finds

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

Related Keywords

Poland ,Bydgoszcz ,Kujawsko Pomorskie ,Warsaw ,L67 ,Polish ,Malgorzata Pawlowska ,Society Of Epidemiologists ,Nicolaus Copernicus University ,World Health Organization ,Polish Society ,Infectious Disease ,World Efficacy ,Pibrentasvir Regimen ,Hepatitis C ,Thcv ,Daa ,Direct Acting Antivirals ,Pangenotypic ,Svr ,Sustained Viral Response ,Glecaprevir ,Pibrentasvir ,Children ,Pediatric ,Patients ,Safety ,Efficacy ,Adverse Events ,